# A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients

> **NCT05744063** · PHASE4 · COMPLETED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 13 (actual)

## Conditions studied

- Primary Hemophagocytic Lymphohistiocytosis

## Interventions

- **DRUG:** Emapalumab-Lzsg 5 MG/ML [Gamifant]

## Key facts

- **NCT ID:** NCT05744063
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-03
- **Primary completion:** 2025-02-21
- **Final completion:** 2025-08-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05744063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05744063, "A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05744063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*